Key Takeaway: Helus Pharma has announced that its APPROACH Phase 3 clinical trial for HLP003, aimed at treating major depressive disorder, is progressing well, with over 86% of enrollment completed. The previous Phase 2 trial results indicated a substantial long-term efficacy, showing a reduction of approximately 23 points on the Montgomery-Asberg Depression Rating Scale.
Price reaction · baseline $4.85 (2026-06-23 close) · hit pre-market · 4 other HELP headline(s) in the window, move may be shared
day 0 close
+4.9%
day 1
+24.1%
day 3 · peak
+41.9%
Market Sentiment Analysis
POSITIVE FACTORS
Enrollment for the APPROACH Phase 3 trial has surpassed 86%.
Phase 2 data showed long-term efficacy of HLP003.
HLP003 demonstrated a significant reduction in depression rating scores.
Full Press Release Details
- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder (“MDD”) is progressing as planned and has surpassed 86% enrollment - - Phase 2 HLP003 data demonstrated long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale
Frequently Asked Questions
What is the APPROACH Phase 3 trial about?
The APPROACH Phase 3 trial is focused on HLP003 for treating major depressive disorder.
How much of the trial enrollment has been completed?
The trial has surpassed 86% enrollment.
What did Phase 2 data show for HLP003?
Phase 2 data demonstrated long-term efficacy with a ~23-point reduction in depression scores.